CCIA
MLTX icon

Campbell & Co Investment Adviser’s MoonLake Immunotherapeutics MLTX Stock Holding History

Campbell & Co Investment Adviser’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$578K Buy
+29,678
New +$538K 0.03% 724
2026
Q1 		– Sell
-13,448
Closed -$177K – 1280
2025
Q4 		$177K Buy
+13,448
New +$159K 0.01% 1067

Other funds holding MLTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Campbell & Co Investment Adviser's MLTX Position: Q2 2026 in Review

Campbell & Co Investment Adviser opened a new position in MoonLake Immunotherapeutics (MLTX) in Q2 2026: 29,678 shares worth $578K. The stake represents 0.03% of the portfolio and ranks #724 among its holdings. This is a return to the name: Campbell & Co Investment Adviser previously reported a position in MLTX as recently as Q4 2025.

Campbell & Co Investment Adviser first reported a position in MLTX in Q4 2025 and has held it in 2 quarters since. 40 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Campbell & Co Investment Adviser held 29,678 shares of MoonLake Immunotherapeutics worth $578K as of Q2 2026.
  • MoonLake Immunotherapeutics was a new Campbell & Co Investment Adviser position in Q2 2026.
  • MoonLake Immunotherapeutics made up 0.03% of Campbell & Co Investment Adviser's portfolio in Q2 2026, its #724 holding.
  • Campbell & Co Investment Adviser first reported a position in MoonLake Immunotherapeutics in Q4 2025 and has held it in 2 quarters since.
  • 40 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.